Advances in the management of myeloma bone disease

Claire M. Shipman, Babatunde O. Oyajobi, Gregory R. Mundy

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Multiple myeloma is the second most common adult haematological malignancy. One of the major clinical features is the development of a unique osteolytic bone disease, characterised by progressive and devastating bone destruction, bone pain, pathological fractures and hypercalcaemia. Bisphosphonates, inhibitors of osteoclastic bone resorption, are the standard therapy for myeloma-induced bone disease. However, as our understanding of the molecular mechanisms involved in the development of myeloma bone disease increases, new molecular targets have been identified for the treatment of this devastating bone disease.

Original languageEnglish (US)
Pages (from-to)2781-2791
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Issue number16
StatePublished - Dec 2005


  • Bisphosphonate
  • Multiple myeloma
  • Osteoblast
  • Osteoclast

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Advances in the management of myeloma bone disease'. Together they form a unique fingerprint.

Cite this